In line with the critical role of PRMT1 in suppressing tumor immune surveillance, relatively higher PRMT1 expression level predicted lower cytotoxic T lymphocytes (CTL) infiltration and a worse prognosis for patients with BRCA (Fig. 4i, j), metastatic melanoma (Fig. 4k, l), and several other cancer types, including multiple myeloma (MM, Supplementary Fig. 4h) and neuroblastoma (NB, Supplementary Fig. 4i). This evidence concerns the gene PRMT1 and neuroblastoma.